These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

479 related items for PubMed ID: 11320385

  • 1. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
    Lin FY, Ho VA, Khiem HB, Trach DD, Bay PV, Thanh TC, Kossaczka Z, Bryla DA, Shiloach J, Robbins JB, Schneerson R, Szu SC.
    N Engl J Med; 2001 Apr 26; 344(17):1263-9. PubMed ID: 11320385
    [Abstract] [Full Text] [Related]

  • 2. Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children.
    Canh DG, Lin FY, Thiem VD, Trach DD, Trong ND, Mao ND, Hunt S, Schneerson R, Robbins JB, Chu C, Shiloach J, Bryla DA, Bonnet MC, Schulz D, Szu SC.
    Infect Immun; 2004 Nov 26; 72(11):6586-8. PubMed ID: 15501790
    [Abstract] [Full Text] [Related]

  • 3. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
    Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB, Trach DD, Karpas A, Hunt S, Bryla DA, Schneerson R, Robbins JB, Szu SC.
    Infect Immun; 1999 Nov 26; 67(11):5806-10. PubMed ID: 10531232
    [Abstract] [Full Text] [Related]

  • 4. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
    Salman M, St Michael F, Ali A, Jabbar A, Cairns C, Hayes AC, Rahman M, Iqbal M, Haque A, Cox AD.
    J Immunol Methods; 2017 Nov 26; 450():27-33. PubMed ID: 28735760
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M, Shah N, Ghosh A, Chatterjee S, Kaur I, Bhattacharya N, Basu S.
    Hum Vaccin Immunother; 2016 Apr 02; 12(4):939-45. PubMed ID: 26901576
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
    Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, Anemona A, Habib MA, Alberto E, Juvekar S, Khan RM, Marhaba R, Ali N, Malubay N, Kawade A, Saul A, Martin LB, Podda A.
    Lancet Infect Dis; 2014 Feb 02; 14(2):119-29. PubMed ID: 24290843
    [Abstract] [Full Text] [Related]

  • 11. Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine.
    Szu SC, Lin KF, Hunt S, Chu C, Thinh ND.
    Vaccine; 2014 May 07; 32(22):2618-22. PubMed ID: 24657719
    [Abstract] [Full Text] [Related]

  • 12. Vaccines for preventing typhoid fever.
    Anwar E, Goldberg E, Fraser A, Acosta CJ, Paul M, Leibovici L.
    Cochrane Database Syst Rev; 2014 Jan 02; (1):CD001261. PubMed ID: 24385413
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a.
    Darton TC, Jones C, Blohmke CJ, Waddington CS, Zhou L, Peters A, Haworth K, Sie R, Green CA, Jeppesen CA, Moore M, Thompson BA, John T, Kingsley RA, Yu LM, Voysey M, Hindle Z, Lockhart S, Sztein MB, Dougan G, Angus B, Levine MM, Pollard AJ.
    PLoS Negl Trop Dis; 2016 Aug 02; 10(8):e0004926. PubMed ID: 27533046
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
    Ni Y, Springer MJ, Guo J, Finger-Baker I, Wilson JP, Cobb RR, Turner D, Tizard I.
    Vaccine; 2017 Dec 18; 35(51):7121-7126. PubMed ID: 29150208
    [Abstract] [Full Text] [Related]

  • 19. Vi Capsular Polysaccharide Produced by Recombinant Salmonella enterica Serovar Paratyphi A Confers Immunoprotection against Infection by Salmonella enterica Serovar Typhi.
    Xiong K, Zhu C, Chen Z, Zheng C, Tan Y, Rao X, Cong Y.
    Front Cell Infect Microbiol; 2017 Dec 18; 7():135. PubMed ID: 28484685
    [Abstract] [Full Text] [Related]

  • 20. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
    Zhou WZ, Koo HW, Wang XY, Zhang J, Park JK, Zhu F, Deen J, Acosta CJ, Chen Y, Wang H, Galindo CM, Ochiai L, Park T, von Seidlein L, Xu ZY, Clemens JD.
    Pediatr Infect Dis J; 2007 Nov 18; 26(11):1001-5. PubMed ID: 17984806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.